XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Common stock
Retained earnings
Accumulated other comprehensive income (loss)
Common stock shares outstanding, beginning balance (in shares) at Dec. 31, 2020   21,796,904    
Beginning balance at Dec. 31, 2020 $ 717,750 $ 278,505 $ 403,888 $ 35,357
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 58,820   58,820  
Share-based compensation expense 1,665 $ 1,665    
Common stock issued - Option exercise; stock grants (in shares)   193,365    
Common stock issued - Option exercise; stock grants 2,044 $ 2,044    
Other comprehensive income (loss) (7,511)     (7,511)
Dividends declared on common stock (10,912)   (10,912)  
Common stock repurchased (in shares)   (1,198,610)    
Common stock repurchased (53,125) $ (21,440) (31,685)  
Common stock shares outstanding, ending balance (in shares) at Jun. 30, 2021   20,791,659    
Ending balance at Jun. 30, 2021 708,731 $ 260,774 420,111 27,846
Common stock shares outstanding, beginning balance (in shares) at Mar. 31, 2021   21,360,514    
Beginning balance at Mar. 31, 2021 701,463 $ 269,942 411,712 19,809
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 29,157   29,157  
Share-based compensation expense 855 $ 855    
Common stock issued - Option exercise; stock grants (in shares)   5,108    
Common stock issued - Option exercise; stock grants 195 $ 195    
Other comprehensive income (loss) 8,037     8,037
Dividends declared on common stock (5,378)   (5,378)  
Common stock repurchased (in shares)   (573,963)    
Common stock repurchased (25,598) $ (10,218) (15,380)  
Common stock shares outstanding, ending balance (in shares) at Jun. 30, 2021   20,791,659    
Ending balance at Jun. 30, 2021 $ 708,731 $ 260,774 420,111 27,846
Common stock shares outstanding, beginning balance (in shares) at Dec. 31, 2021 20,085,336 20,085,336    
Beginning balance at Dec. 31, 2021 $ 715,339 $ 249,856 444,343 21,140
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 37,672   37,672  
Share-based compensation expense 2,297 $ 2,297    
Common stock issued - Option exercise; stock grants (in shares)   126,218    
Common stock issued - Option exercise; stock grants 0      
Other comprehensive income (loss) (84,403)     (84,403)
Dividends declared on common stock (13,797)   (13,797)  
Common stock repurchased (in shares)   (1,498,765)    
Common stock repurchased $ (76,341) $ (27,377) (48,964)  
Common stock shares outstanding, ending balance (in shares) at Jun. 30, 2022 18,712,789 18,712,789    
Ending balance at Jun. 30, 2022 $ 580,767 $ 224,776 419,254 (63,263)
Common stock shares outstanding, beginning balance (in shares) at Mar. 31, 2022   18,700,536    
Beginning balance at Mar. 31, 2022 601,231 $ 223,718 408,442 (30,929)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 17,721   17,721  
Share-based compensation expense 1,221 $ 1,221    
Common stock issued - Option exercise; stock grants (in shares)   21,378    
Common stock issued - Option exercise; stock grants 0 $ 0    
Other comprehensive income (loss) (32,334)     (32,334)
Dividends declared on common stock (6,633)   (6,633)  
Common stock repurchased (in shares)   (9,125)    
Common stock repurchased $ (439) $ (163) (276)  
Common stock shares outstanding, ending balance (in shares) at Jun. 30, 2022 18,712,789 18,712,789    
Ending balance at Jun. 30, 2022 $ 580,767 $ 224,776 $ 419,254 $ (63,263)